Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Incyte (INCY) PT Lowered to $92 at RBC Capital Following Earnings
May 4, 2021 12:51 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Incyte (NASDAQ: INCY) to $92.00 (from $93.00) while maintaining a Sector Perform rating following reults.
The analyst commented, "A soft quarter for INCY from combined pandemic/seasonal oncology headwinds, though signs suggest to us... More
Incyte (INCY) Tops Q1 EPS by 4c
May 4, 2021 7:18 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of $0.67, $0.04 better than the analyst estimate of $0.63. Revenue for the quarter came in at $605 million versus the consensus estimate of $656.88 million.
2021... More
